Welcome!

News Feed Item

Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

https://www.reportbuyer.com/product/2276221/Co-development-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter co-development deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of co-development dealmaking and business activities.

The initial chapters of this report provide an orientation of co-development dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-development as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of co-development deals. The chapter includes numerous case studies to enable understanding of both pure co-development deals and multicomponent deals where co-development forms a part.

Chapter 4 provides a review of the leading co-development deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of co-development financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of co-development deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of co-development deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in co-development dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-development as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.

Report scope

Co-development Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading life science companies worldwide.

Co-development Terms and Agreements in Pharma, Biotech and Diagnostics includes:

Trends in co-development dealmaking in the biopharma industry since 2009
Analysis of co-development deal structure
Case studies of real-life co-development deals
Comprehensive listing of co-development deals since 2009
Access to co-development contract documents
Key financial benchmarks for headline, upfront, milestone and royalty rates
The leading co-development deals by value since 2009
Most active co-development dealmakers since 2009
The leading co-development partnering resources

In Co-development Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access to available contract documents for co-development deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How do milestone align with clinical stage development phases?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in co-development dealmaking

2.1. Introduction
2.2. Definition of co-development deals
2.3. Success factors for co-development deals
2.4. When co-development can be useful
2.5. Attributes of co-development deals
2.6. Aligning partners to make the co-development work
2.7. Trends in co-development deals since 2009
2.8. Option to co-develop
2.9. The future of co-development deals

Chapter 3 – Overview of co-development deal structure

3.1. Introduction
3.2. Pure versus multi-component co-development deals
3.3. Pure co-development agreement structure
3.3.1. Example co-development agreements
3.3.1.a. Case study 1: Ambrx – Zhejiang Medicine – June 2013
3.3.1.b. Case study 2: UniQure - Chiesi – July 2013

Chapter 4 – Leading co-development deals

4.1. Introduction
4.2. Top co-development deals by value
4.3. Most active co-development dealmakers
4.4. Bigpharma co-development deal activity

Chapter 5 – Bigpharma co-development deals

5.1. Introduction
5.2. How to use co-development deals
5.3. Company co-development agreement listings

Chapter 6 – Bigbiotech co-development deals

6.1. Introduction
6.2. How to use co-development deals
6.3. Company co-development agreement listings

Chapter 7 – Co-development contract directory 2009-2014

7.1. Introduction
7.2. Company A-Z
7.3. By therapy area
Anaesthetics
Cardiovascular
Central Nervous System
Dermatology
Gastrointestinal
Genetic disorders
Gynecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Psychiatry
Public health
Respiratory
7.4. By stage of development at signing
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
7.5. By technology area
Antibodies
Assays
Biological compounds
Biomarkers
Biomaterials
Biosimilars/Bio-betters
Clinical testing
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Equipment
Gene therapy
Genomics
Industrial chemicals
Nanotechnology
Natural product
Oligonucleotide
Peptides
Processes
Proteomics
Recombinant DNA
Research services
RNA therapeutics
Screening
Small molecules
Software tools
Vaccines

Appendix

Appendix 1 – Co-development references
Appendix 2 – Resources
Appendix 3 – Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Order Form – Upgrades to subscription access products
Recent report titles from CurrentPartnering
Order Form – Reports

Separate appendix file supplied for:

Appendix 1 – Co-development dealmaking - by financial disclosure
Appendix 2 – Co-development dealmaking - by companies A-Z
Appendix 3 – Co-development dealmaking - by stage of development
Appendix 4 – Co-development dealmaking - by therapeutic target
Appendix 5 – Co-development dealmaking - by technology type

TABLE OF FIGURES

Figure 1: Definition of co-development
Figure 2: Situations where co-development can prove useful
Figure 3: Key components of a co-development deal
Figure 4: Issues in implementing co-development agreements
Figure 5: Trends in co-development deal announcements, 2009-2014
Figure 6: Co-development deals signed at each phase of development, 2009-2013
Figure 7: Co-development agreements – what should a contract include?
Figure 8: Components of the co-development deal structure
Figure 9: Top co-development deals by value since 2009
Figure 10: Most active co-development dealmakers 2009-2014
Figure 11: Bigpharma – top 50 – Co-development deals 2007 to 2013
Figure 12: Bigpharma co-development deal frequency - 2009 to 2014
Figure 13: Online partnering resources
Figure 14: Deal type definitions

Read the full report:
Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

https://www.reportbuyer.com/product/2276221/Co-development-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
Translating agile methodology into real-world best practices within the modern software factory has driven widespread DevOps adoption, yet much work remains to expand workflows and tooling across the enterprise. As models evolve from pockets of experimentation into wholescale organizational reinvention, practitioners find themselves challenged to incorporate the culture and architecture necessary to support DevOps at scale. In his session at @DevOpsSummit at 20th Cloud Expo, Anand Akela, Senior...
Join IBM November 2 at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how to go beyond multi-speed it to bring agility to traditional enterprise applications. Technology innovation is the driving force behind modern business and enterprises must respond by increasing the speed and efficiency of software delivery. The challenge is that existing enterprise applications are expensive to develop and difficult to modernize. This often results in what Gartner calls ...
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
Did you know that you can develop for mainframes in Java? Or that the testing and deployment can be automated across mobile to mainframe? In his session at @DevOpsSummit at 20th Cloud Expo, Vaughn Marshall, Sr. Principal Product Owner at CA Technologies, will discuss and demo how increasingly teams are developing with agile methodologies using modern development environments and automating testing and deployments, mobile to mainframe.
SYS-CON Events announced today that Hitachi Data Systems, a wholly owned subsidiary of Hitachi LTD., will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City. Hitachi Data Systems (HDS) will be featuring the Hitachi Content Platform (HCP) portfolio. This is the industry’s only offering that allows organizations to bring together object storage, file sync and share, cloud storage gateways, and sophisticated search an...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...